3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Carboplatin
359
Pemetrexed
275
Cisplatin
229
Paclitaxel
212
Docetaxel
205
Gemcitabine
160
Erlotinib Hydrochloride
150
Bevacizumab
132
pembrolizumab
128
Radiotherapy
112
Nivolumab
88
durvalumab
84
Drug Therapy
84
osimertinib
81
atezolizumab
58
Vinorelbine
53
Gefitinib
53
Radiosurgery
49
Cetuximab
39
Taxes
37
130-nm albumin-bound paclitaxel
36
Ipilimumab
34
anlotinib
33
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
33
Etoposide
30
Albumin-Bound Paclitaxel
29
tislelizumab
27
icotinib
27
Specimen Handling
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Non-Small-Cell Lung
×
taletrectinib
×
Clear all
NCT04919811
2026-01-07
TRUST-II
Nuvation Bio Inc.
Phase 2
Active not recruiting
217 enrolled
1 FDA